A Phase 1, Multicenter, Open-label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects with Relapsed or Refractory B-cell Malignancies

Administered By

Awarded By

Contributors

Start/End

  • October 22, 2021 - October 17, 2026